Cells to Surgery Quiz: April 2020
Studysummary This source reports that a study by Liu et al. analyzed genetic factors influencing adalimumab response in hidradenitis suppurativa, finding a specific genetic variant (SNP rs59532114) associated with an inadequate response to the treatment due to increased abscess and inflammatory nodule counts.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The "Cells to Surgery Quiz: April 2020" document from the Journal of Investigative Dermatology focused on diagnosing and managing hidradenitis suppurativa (HS), a chronic inflammatory skin disorder. It emphasized that routine incision and drainage (I&D) was ineffective for HS due to high recurrence rates, recommending punch debridement or unroofing instead. Topical clindamycin was noted as a first-line treatment for mild HS, while acitretin was preferred for more severe cases. A population-based cohort study involving 5,964 HS patients and 29,404 controls revealed significantly increased risks of cardiovascular-associated death and other major adverse cardiovascular events in HS patients. Additionally, a genetic study identified SNPs associated with adalimumab response, highlighting the need for personalized treatment approaches.
